Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

RBC Capital Remains a Buy on CVS Health (CVS)

Tipranks - Tipranks - Fri Apr 10, 6:12AM CDT

RBC Capital analyst Ben Hendrix maintained a Buy rating on CVS Health yesterday and set a price target of $93.00. The company’s shares closed yesterday at $78.79.

Easter Sale - 70% Off TipRanks

According to TipRanks, Hendrix is a 4-star analyst with an average return of 5.6% and a 50.96% success rate. Hendrix covers the Healthcare sector, focusing on stocks such as Brookdale Senior Living, HCA Healthcare, and Tenet Healthcare.

CVS Health has an analyst consensus of Strong Buy, with a price target consensus of $96.33, a 22.26% upside from current levels. In a report released on April 7, Bank of America Securities also maintained a Buy rating on the stock with a $95.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on CVS Health’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $105.69 billion and a net profit of $2.94 billion. In comparison, last year the company earned a revenue of $97.71 billion and had a net profit of $1.64 billion

Read More on CVS:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).